DE-117 Spectrum 5 Study

Summary

Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost low/non-responder subjects diagnosed with POAG or OHT

Timeline

Start

2018-09-27

Primary completion

2022-01-13

Completion

2022-01-13

Outcome

Met primary endpoint

paper was an additional decrease of 2.96 mm Hg (2.83) ( P <0.0001). PMID 37853676 ↗

Publications

• Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A. Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study. J Glaucoma. 2023 Dec 1;32(12):999-1005. doi: 10.1097/IJG.0000000000002321. Epub 2023 Oct 17.

Drugs

Indications